Cost savings using a test-based de-escalation strategy for patients with Crohn's disease in remission on optimized infliximab: A discrete event model study.

Date publication

janvier 2019

Journal

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Attar A, Duru G, Roblin X, Savarieau B, Brunel P, Lamure M, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30268737

Résumé

Drug de-escalation is considered in Crohn's disease patients in sustained remission on optimized infliximab treatment.

Mots clés

Cost saving, Crohn’s disease, Drug de-escalation, Infliximab

Référence

Dig Liver Dis. 2019 01;51(1):112-119